167 related articles for article (PubMed ID: 37185394)
1. Injectable Synthetic Beta-Tricalcium Phosphate/Calcium Sulfate (GeneX) for the Management of Contained Defects Following Curettage of Benign Bone Tumours.
Razii N; Docherty LM; Halai M; Mahendra A; Gupta S
Curr Oncol; 2023 Mar; 30(4):3697-3707. PubMed ID: 37185394
[TBL] [Abstract][Full Text] [Related]
2. Adverse reactions of artificial bone graft substitutes: lessons learned from using tricalcium phosphate geneX®.
Friesenbichler J; Maurer-Ertl W; Sadoghi P; Pirker-Fruehauf U; Bodo K; Leithner A
Clin Orthop Relat Res; 2014 Mar; 472(3):976-82. PubMed ID: 24078171
[TBL] [Abstract][Full Text] [Related]
3. Time to full weight-bearing with the use of a calcium sulfate-calcium phosphate bone substitute as a bone void filler following extended curettage in the treatment of primary benign bone tumours.
Gyemi L; Selznick A; Petrisor B; Ghert M
J Orthop Surg (Hong Kong); 2024; 32(2):10225536241254200. PubMed ID: 38733211
[TBL] [Abstract][Full Text] [Related]
4. Aqueous calcium sulphate as bone graft for voids following open curettage of bone tumours.
Johnson LJ; Clayer M
ANZ J Surg; 2013 Jul; 83(7-8):564-70. PubMed ID: 22925525
[TBL] [Abstract][Full Text] [Related]
5. Use of a calcium sulfate-calcium phosphate synthetic bone graft composite in the surgical management of primary bone tumors.
Evaniew N; Tan V; Parasu N; Jurriaans E; Finlay K; Deheshi B; Ghert M
Orthopedics; 2013 Feb; 36(2):e216-22. PubMed ID: 23380017
[TBL] [Abstract][Full Text] [Related]
6. Long-term Follow-up of the Use of a Synthetic Bone Graft Composite in the Surgical Management of Primary Bone Tumors.
Multani I; Schneider P; Baldawi H; Deheshi B; Ghert M
Orthopedics; 2018 Nov; 41(6):e868-e875. PubMed ID: 30371921
[TBL] [Abstract][Full Text] [Related]
7. Unexpected radiographic lucency following grafting of bone defects with calcium sulfate/tricalcium phosphate bone substitute.
Auston DA; Feibert M; Craig T; Damron TA
Skeletal Radiol; 2015 Oct; 44(10):1453-9. PubMed ID: 26081807
[TBL] [Abstract][Full Text] [Related]
8. A new β-tricalcium phosphate with uniform triple superporous structure as a filling material after curettage of bone tumor.
Seto S; Muramatsu K; Hashimoto T; Tominaga Y; Taguchi T
Anticancer Res; 2013 Nov; 33(11):5075-81. PubMed ID: 24222152
[TBL] [Abstract][Full Text] [Related]
9. Treatment alternatives and clinical outcomes of bone filling after benign tumour curettage. A systematic review.
Gava NF; Engel EE
Orthop Traumatol Surg Res; 2022 Jun; 108(4):102966. PubMed ID: 34033919
[TBL] [Abstract][Full Text] [Related]
10. Grafting using injectable calcium sulfate in bone tumor surgery: comparison with demineralized bone matrix-based grafting.
Kim JH; Oh JH; Han I; Kim HS; Chung SW
Clin Orthop Surg; 2011 Sep; 3(3):191-201. PubMed ID: 21909466
[TBL] [Abstract][Full Text] [Related]
11. No local recurrence of enchondroma after curettage and plaster filling.
Gaasbeek RD; Rijnberg WJ; van Loon CJ; Meyers H; Feith R
Arch Orthop Trauma Surg; 2005 Feb; 125(1):42-5. PubMed ID: 15723246
[TBL] [Abstract][Full Text] [Related]
12. Chronology of the Radiographic Appearances of the Calcium Sulfate-Calcium Phosphate Synthetic Bone Graft Composite Following Resection of Bone Tumors: A Follow-up Study of Postoperative Appearances.
Tan V; Evaniew N; Finlay K; Jurriaans E; Ghert M; Deheshi B; Parasu N
Can Assoc Radiol J; 2016 Feb; 67(1):21-7. PubMed ID: 25599610
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of ultraporous β-tricalcium phosphate (vitoss) as bone graft substitute for cavitary defects in benign and low-grade malignant bone tumors.
Van Hoff C; Samora JB; Griesser MJ; Crist MK; Scharschmidt TJ; Mayerson JL
Am J Orthop (Belle Mead NJ); 2012 Jan; 41(1):20-3. PubMed ID: 22389890
[TBL] [Abstract][Full Text] [Related]
14. Ultraporous β-tricalcium phosphate alone or combined with bone marrow aspirate for benign cavitary lesions: comparison in a prospective randomized clinical trial.
Damron TA; Lisle J; Craig T; Wade M; Silbert W; Cohen H
J Bone Joint Surg Am; 2013 Jan; 95(2):158-66. PubMed ID: 23324964
[TBL] [Abstract][Full Text] [Related]
15. Function after injection of benign bone lesions with a bioceramic.
Fillingham YA; Lenart BA; Gitelis S
Clin Orthop Relat Res; 2012 Jul; 470(7):2014-20. PubMed ID: 22290129
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of calcium sulfate artificial bone graft versus allograft in the reconstruction of bone defect after tumor curettage.
Yang Y; Niu X; Zhang Q; Hao L; Ding Y; Xu H
Chin Med J (Engl); 2014; 127(17):3092-7. PubMed ID: 25189951
[TBL] [Abstract][Full Text] [Related]
17. Use of purified beta-tricalcium phosphate for filling defects after curettage of benign bone tumours.
Hirata M; Murata H; Takeshita H; Sakabe T; Tsuji Y; Kubo T
Int Orthop; 2006 Dec; 30(6):510-3. PubMed ID: 16736145
[TBL] [Abstract][Full Text] [Related]
18. Filling of the resultant cavity after curettage of benign bone tumours is still controversial.
Ismail TB; Mahmoud MM; Ahmed OE; Bola AH; Bahaa ZH
Med J Malaysia; 2023 Mar; 78(2):163-170. PubMed ID: 36988525
[TBL] [Abstract][Full Text] [Related]
19. The use of a surgical grade calcium sulfate as a bone graft substitute: results of a multicenter trial.
Kelly CM; Wilkins RM; Gitelis S; Hartjen C; Watson JT; Kim PT
Clin Orthop Relat Res; 2001 Jan; (382):42-50. PubMed ID: 11154003
[TBL] [Abstract][Full Text] [Related]
20. Treatment of benign bone lesions with an injectable calcium sulfate-based bone graft substitute.
Kelly CM; Wilkins RM
Orthopedics; 2004 Jan; 27(1 Suppl):s131-5. PubMed ID: 14763545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
